Vnitr Lek 2007, 53(4):408-411
Side effects of pharmacotherapy on lipid levels
- III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. ©těpán Svačina, DrSc., MBA
Modern and effective pharmacotherapy for hypolipidemia usually compensates the negative effect of certain groups of drugs on lipid levels. Nevertheless, the fact that some psychotropic, antiepileptic, antihypertensive or hormonal drugs may have a certain negative impact should be taken into consideration. The article provides an overview of some of the drug groups provoking dyslipidemia, as well as an overview of drugs with a positive effect on dyslipidemia.
Keywords: cholesterol; triglycerides; metabolic syndrome; psychotropic drugs; antiepileptic drugs; antihypertensive drugs; hormonal replacement therapy; contraception; antidiabetic drugs
Received: April 1, 2007; Published: April 1, 2007 Show citation
References
- Papakostas GI et al. Serum cholesterol in treatment-resistant depression. Neuropsychobiology 2003; 47: 146-151.
Go to original source...
Go to PubMed...
- Mahadik SP, Evans DR. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatr Clin North Am 2003; 26: 85-102.
Go to original source...
Go to PubMed...
- Peters H et al. Serum cholesterol level comparison: control subjects, anxiety disorder patients, and obsessive-compulsive disorder patients. Can J Psychiatry 2002; 47: 557-562.
Go to original source...
Go to PubMed...
- Almeida-Montes LG et al. Relation of serum cholesterol, lipid, serotonin and tryptophan levels to severity of depression and to suicide attempts. J Psychiatry Neurosci 2000; 25: 371-377.
- Svačina ©. Metabolické účinky psychofarmak. Praha: Triton 2004.
- Melkerssson KI et al. Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizofrenia or related psychoses. J Clin Psychiatry 2000; 61: 742-749.
Go to original source...
Go to PubMed...
- Almeras A et al. Development of an atheriogenic metabolic risk. Profile associated with the use of some atypical neuroleptics. Proc North Am Assoc Obesity 2001; 54: 46.
- Bettinger TL et al. Olanzapine induced glucose dysregulation. Ann Pharmacother 2000; 34: 865-867.
Go to original source...
Go to PubMed...
- Atmaca M et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003; 64: 598-604.
Go to original source...
Go to PubMed...
- Cohen S et al. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. J Clin Psychiatry 2003; 64: 60-62.
Go to original source...
Go to PubMed...
- Lindenmayer JP et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290-296.
Go to original source...
Go to PubMed...
- ©mahelová A. Akutní komplikace diabetu. Praha: Triton 2006.
- Wetterling T. Hyperlipidemia - side-effect of the treatment with an atypical antipsychotic (zotepine)? Psychiatr Prax 2002; 29: 438-440.
Go to original source...
Go to PubMed...
- McGavin JK, Goa KL. Aripiprazole. CNS Drugs 2002; 16: 779-786.
Go to original source...
Go to PubMed...
- Appolinario JC et al. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit 2004; 10: MT50-MT52.
- ©mahelová A et al. Significance of plant sterols in diabetes. Vnitř Lék 2004; 50: 147-152.
Go to PubMed...
- Bramswig S et al. Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults. Am J Physiol Heart Circ Physiol 2002; 282: H704-H716.
Go to original source...
Go to PubMed...
- Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996; 93: 1976-1980.
Go to original source...
Go to PubMed...
- Sonawalla SB et al. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics 2002; 43: 310-316.
Go to original source...
Go to PubMed...
- de Zwaan M, Nutzinger DO. Effect of fluvoxamine on total serum cholesterol levels during weight reduction. J Clin Psychiatry 1996; 57: 346-348.
- Yang CC, Jick SS, Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 2003; 163: 1926-1932.
Go to original source...
Go to PubMed...
- Svačina © et al. Metabolický syndrom. Praha: Triton 2006.
- Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998; 11: 1258-1265.
Go to original source...
Go to PubMed...
- Svačina ©. Hypertenze při obezitě a diabetu. Praha: Triton 2006.
- Ernsberger P. The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. Ann N Y Acad Sci 2003; 1009: 251-261.
Go to original source...
Go to PubMed...
- Scemama M, Fevrier B, Beucler I et al. Effects of rilmenidine (hyperium) on lipid balance in hyperlipidemic hypertensive patients. Randomized, controlled, double-blind 8-week study vs captopril in parallel groups. Ann Cardiol Angeiol (Paris) 1996; 45: 595-601.
Go to PubMed...
- Widimsky J, Sirotiakova J. Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome. Curr Med Res Opin 2006; 22: 1287-1294.
Go to original source...
Go to PubMed...
- Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005; 71: 409-416.
Go to original source...
Go to PubMed...
- et al. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial 2007; 92: 456-461.
Go to original source...
Go to PubMed...
- et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. 2006; 8: 538-554.
Go to original source...
Go to PubMed...
- Engin-Ustun Y et al. Effects of intranasal 17beta-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: a randomized, placebo-controlled clinical trial. 2006; 22: 676-679.
Go to original source...
Go to PubMed...
- Alagozlu H et al. Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis 2006; 26: 297-302.
Go to original source...
Go to PubMed...
- Gillett MJ, Burnett JR, Yeap D. Clomiphene-associated combined hyperlipidemia: a case report. J Reprod Med 2006; 51: 587-590.
Go to PubMed...
- Tugrul S et al. Comparison of two forms of continuous combined hormone replacement therapy with respect to metabolic effects 2007; 275: 335-339.
- Haluzík M, Svačina ©. Metabolický syndrom a jaderné receptory PPAR. Praha: Grada 2005.
- Haberbosch W. Effects of Thiazolidinediones on Dyslipidemia in Patients with Type 2 Diabetes. Are All Equally Vasoprotective? 2007; 32: 51-57.
- Chappuis B et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. 2007; 8: Epub.
Go to original source...
Go to PubMed...
- Rosenstock J et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. 2007; 30: 217-223.
Go to original source...
Go to PubMed...
- Kothare PA et al. Exenatide effects on statin pharmacokinetics and lipid response. 2007; 45: 114-120.